Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Short Interest Down 14.9% in February

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) was the target of a significant drop in short interest in the month of February. As of February 28th, there was short interest totalling 3,940,000 shares, a drop of 14.9% from the February 13th total of 4,630,000 shares. Based on an average daily volume of 895,400 shares, the days-to-cover ratio is presently 4.4 days. Approximately 7.1% of the shares of the stock are short sold.

Insider Activity

In related news, insider Tsveta Milanova sold 2,804 shares of Agios Pharmaceuticals stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $32.18, for a total value of $90,232.72. Following the sale, the insider now directly owns 18,906 shares in the company, valued at approximately $608,395.08. The trade was a 12.92 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Company insiders own 4.93% of the company’s stock.

Institutional Investors Weigh In On Agios Pharmaceuticals

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. grew its holdings in shares of Agios Pharmaceuticals by 1.5% during the 4th quarter. Vanguard Group Inc. now owns 5,631,321 shares of the biopharmaceutical company’s stock worth $185,045,000 after purchasing an additional 85,339 shares during the period. State Street Corp lifted its position in Agios Pharmaceuticals by 10.2% in the third quarter. State Street Corp now owns 2,331,433 shares of the biopharmaceutical company’s stock valued at $103,586,000 after buying an additional 216,484 shares during the last quarter. Erste Asset Management GmbH purchased a new position in Agios Pharmaceuticals during the third quarter worth about $97,199,000. Jefferies Financial Group Inc. purchased a new position in Agios Pharmaceuticals during the fourth quarter worth about $49,290,000. Finally, Geode Capital Management LLC increased its position in shares of Agios Pharmaceuticals by 0.5% during the third quarter. Geode Capital Management LLC now owns 1,357,531 shares of the biopharmaceutical company’s stock valued at $60,326,000 after acquiring an additional 6,101 shares during the last quarter.

Analysts Set New Price Targets

AGIO has been the topic of a number of research analyst reports. Royal Bank of Canada lifted their price target on Agios Pharmaceuticals from $55.00 to $57.00 and gave the stock an “outperform” rating in a research note on Tuesday, December 10th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Agios Pharmaceuticals in a research note on Wednesday, December 18th. HC Wainwright assumed coverage on shares of Agios Pharmaceuticals in a report on Monday, February 24th. They set a “buy” rating and a $58.00 target price for the company. Scotiabank raised their price target on shares of Agios Pharmaceuticals from $53.00 to $75.00 and gave the stock a “sector outperform” rating in a research note on Monday, December 9th. Finally, StockNews.com cut shares of Agios Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, February 14th. One research analyst has rated the stock with a sell rating, four have given a hold rating and five have given a buy rating to the stock. According to MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $56.57.

Agios Pharmaceuticals Trading Down 2.5 %

Agios Pharmaceuticals stock opened at $31.20 on Wednesday. The company has a 50-day moving average price of $33.59 and a 200 day moving average price of $41.56. Agios Pharmaceuticals has a 12-month low of $27.14 and a 12-month high of $62.58. The stock has a market cap of $1.79 billion, a P/E ratio of 2.75 and a beta of 0.90.

Agios Pharmaceuticals (NASDAQ:AGIO) last announced its quarterly earnings results on Thursday, February 20th. The biopharmaceutical company reported ($1.74) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.69) by ($0.05). Agios Pharmaceuticals had a negative return on equity of 2.51% and a net margin of 1,845.92%. As a group, analysts forecast that Agios Pharmaceuticals will post -6.85 EPS for the current year.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.